Biogen signs molecular glue deal, raises yearly projections

Is 2024 the year of molecular glues?

Biogen on Tuesday became the latest company to partner on the increasingly popular subject, teaming up with private …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

AstraZeneca’s KRAS deal with Yusen Jianheng; Abeona gets a PDUFA date

AstraZeneca partners with Chinese biotech: Yusen Jianheng Biopharmaceutical said last week that AstraZeneca will help develop and commercialize a preclinical small molecule that targets the

November 28, 2023

Senate committee plans Nov. 8 vote on wide-ranging health care package

WASHINGTON — The Senate Finance Committee plans to vote Nov. 8 on legislation that includes substance abuse and mental health policies, reforms to drug middlemen’s

October 27, 2023

Astellas Pharma signs deal with Kate Therapeutics for KT430

Kate Therapeutics will use Series A funding and the licence deal to develop genetic medicines to treat FSHD and DM1. Credit: Rabi N. Tawil /

June 9, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.